Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweet GRAS for “Bitter blocker”

This article was originally published in The Tan Sheet

Executive Summary

FDA affirms adenosine monophosphate (AMP) - a natural compound that can be used to block the bitter taste of oral pharmaceuticals - as generally recognized as safe, Linguagen announces Sept. 15. AMP can "improve the taste" of products "without adding excess salt or sugar" and can be used in foods and beverages, Linguagen notes. The Cranbury, N.J.-based firm received a two-year, $746,000 NIH grant in 2002 to conduct research on AMP's ability to block the bitter taste signal pathway caused by pharmaceutical agents (1"The Tan Sheet" Oct. 7, 2002, p. 12)...

You may also be interested in...



OTC Drug Bitter Taste-Blocking Compound Receives $746,000 NIH Grant

NIH-funded research evaluating the efficacy of a bitter taste-inhibiting compound could result in the development of "more palatable" oral OTC drugs and subsequent improvements in patient compliance, according to grantee Linguagen Corp

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel